The incidence of genetic disease alleles in Australian Shepherd dog breed in European countries.

Autor: Majchrakova Z; Slovgen Ltd., Diagnostic Laboratory, Bratislava, Slovakia., Hrckova Turnova E; Comenius University Science Park, Bratislava, Slovakia., Bielikova M; Department of Molecular Biology, Faculty of Natural Sciences, Comenius University, Bratislava, Slovakia., Turna J; Comenius University Science Park, Bratislava, Slovakia.; Department of Molecular Biology, Faculty of Natural Sciences, Comenius University, Bratislava, Slovakia., Dudas A; Department of Molecular Biology, Faculty of Natural Sciences, Comenius University, Bratislava, Slovakia.
Jazyk: angličtina
Zdroj: PloS one [PLoS One] 2023 Feb 27; Vol. 18 (2), pp. e0281215. Date of Electronic Publication: 2023 Feb 27 (Print Publication: 2023).
DOI: 10.1371/journal.pone.0281215
Abstrakt: Genetic disease control is generally not given the importance it deserves. Information about what percentage of individuals carry a disorder-causing mutation is crucial for breeders to produce healthy offspring and maintain a healthy dog population of a particular breed. This study aims to provide information about the incidence of mutant alleles for the most frequently occurring hereditary diseases in the Australian Shepherd dog breed (AS). The samples were collected during a 10-years period (2012-2022) in the European population of the AS. Mutant alleles and incidence were calculated from all the obtained data for all the diseases, specifically: collie eye anomaly (9.71%), canine multifocal retinopathy type 1 (0.53%), hereditary cataract (11.64%), progressive rod-cone degeneration (1.58%), degenerative myelopathy (11.77%) and bob-tail/short-tail (31.74%). Our data provide more information to dog breeders to support their effort to limit the spread of hereditary diseases.
Competing Interests: The authors have read the journal’s policy and the authors of this paper have the following competing interests: ZM is an employee of Slovgen Ltd since 2022 and is participating in a research and development activity that does not conflict with the paper’s content. There are no patents, products in development or marketed products associated with this research to declare. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
(Copyright: © 2023 Majchrakova et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje